Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.55 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 13/20 | 0.54 |
| ▸ | GAA | P10253 | 11/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | GLA | P06280 | 5/20 | 0.54 |
| ▸ | GFER | P55789 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 6/20 | 0.51 |
| ▸ | BLM | P54132 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472182 | 0.82 | RAB9A (0.36) | MEN1KMT2ARXFP1MAPTKDM4E | |
| SCHEMBL24238258 | 0.82 | HPGD (0.51) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Alloxazine SCHEMBL57289 | 0.78 | RAB9A (0.60) | MEN1KMT2AMAPTGAAKDM4E | |
| SCHEMBL3473707 | 0.77 | KMT2A (0.53) | MEN1KMT2AMAPTGAAKDM4E | |
| SCHEMBL864615 | 0.75 | RAB9A (0.57) | MEN1KMT2AMAPTGAAKDM4E | |
| Lumichrome SCHEMBL30432151 | 0.75 | ATM (0.50) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| Lumichrome SCHEMBL974856 | 0.75 | ATM (0.50) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL2251258 | 0.72 | MEN1 (1.00) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL24805247 | 0.71 | ATM (0.40) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL363703 | 0.70 | MEN1 (1.00) | MEN1KMT2ARXFP1CACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164483-B | Pharmaceutical composition for preventing or treating cancer containing PLK1 inhibitor as active ingredient | 国立癌症中心 | 2024-09-24 | — | — | CN | claimed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | claimed |
| WO-2020111325-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT | 국립암센터 | 2020-06-04 | — | — | WO | claimed |
| CN-113164483-B | Pharmaceutical composition for preventing or treating cancer containing PLK1 inhibitor as active ingredient | 国立癌症中心 | 2024-09-24 | — | — | CN | disclosed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
| WO-2020111325-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT | 국립암센터 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | PLK1, PLK2, PLK4 | MEN1 2253/4885KMT2A 1439/4885RXFP1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.